TY - JOUR
T1 - HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
AU - Altunay, B.
AU - Morgenroth, A.
AU - Beheshti, M.
AU - Vogg, A.
AU - Wong, N.C.L.
AU - Ting, H.H.
AU - Biersack, H.J.
AU - Stickeler, E.
AU - Mottaghy, F.M.
N1 - Funding Information:
Open Access funding enabled and organized by Projekt DEAL. BA is supported by an unrestricted grant from Nanomab technologies. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) in the framework of the Research Training Group „Tumor-targeted Drug Delivery" grant 331065168. AM received research funding from Deutsche Krebshilfe grant 70113779. FMM received research funding from the ITN INTRICARE of European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska Curie (grant 722609). .
Publisher Copyright:
© 2020, The Author(s).
PY - 2021/5
Y1 - 2021/5
N2 - Purpose The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a detailed look at recent clinical data from antibody drug conjugates and nanobodies as well as affibodies that are currently under development. Results Clinical and preclinical studies have shown that the use of monoclonal antibodies in molecular imaging is impaired by slow blood clearance, associated with slow and low tumor uptake and with limited tumor penetration potential. Antibody fragments, such as nanobodies, on the other hand, can be radiolabelled with short-lived radioisotopes and provide high-contrast images within a few hours after injection, allowing early diagnosis and reduced radiation exposure of patients. Even in therapy, the small radioactively labeled nanobodies prove to be superior to radioactively labeled monoclonal antibodies due to their higher specificity and their ability to penetrate the tumor. Conclusion While monoclonal antibodies are well established drug delivery vehicles, the current literature on molecular imaging supports the notion that antibody fragments, such as affibodies or nanobodies, might be superior in this approach.
AB - Purpose The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a detailed look at recent clinical data from antibody drug conjugates and nanobodies as well as affibodies that are currently under development. Results Clinical and preclinical studies have shown that the use of monoclonal antibodies in molecular imaging is impaired by slow blood clearance, associated with slow and low tumor uptake and with limited tumor penetration potential. Antibody fragments, such as nanobodies, on the other hand, can be radiolabelled with short-lived radioisotopes and provide high-contrast images within a few hours after injection, allowing early diagnosis and reduced radiation exposure of patients. Even in therapy, the small radioactively labeled nanobodies prove to be superior to radioactively labeled monoclonal antibodies due to their higher specificity and their ability to penetrate the tumor. Conclusion While monoclonal antibodies are well established drug delivery vehicles, the current literature on molecular imaging supports the notion that antibody fragments, such as affibodies or nanobodies, might be superior in this approach.
KW - affibody
KW - anti-her2 nanobody
KW - antibody drug conjugate
KW - emitting radiotherapeutic agent
KW - her2
KW - her2 receptor expression
KW - immunotherapy
KW - in-vivo
KW - monoclonal-antibody
KW - n-succinimidyl
KW - nanobody
KW - preclinical evaluation
KW - residualizing label
KW - single domain antibody
KW - single-domain antibody
KW - trastuzumab emtansine t-dm1
KW - EMITTING RADIOTHERAPEUTIC AGENT
KW - Affibody
KW - MONOCLONAL-ANTIBODY
KW - N-SUCCINIMIDYL
KW - Antibody drug conjugate
KW - Immunotherapy
KW - TRASTUZUMAB EMTANSINE T-DM1
KW - Nanobody
KW - RESIDUALIZING LABEL
KW - HER2 RECEPTOR EXPRESSION
KW - SINGLE-DOMAIN ANTIBODY
KW - Single domain antibody
KW - ANTI-HER2 NANOBODY
KW - IN-VIVO
KW - HER2
KW - PRECLINICAL EVALUATION
U2 - 10.1007/s00259-020-05094-1
DO - 10.1007/s00259-020-05094-1
M3 - (Systematic) Review article
C2 - 33179151
SN - 1619-7070
VL - 48
SP - 1371
EP - 1389
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 5
ER -